In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...
Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.
A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...
8mon
Verywell Health on MSNStages of Chronic Lymphocytic Leukemia (CLL)As CLL progresses and treatment is required, many treatment options are available. Treatments may be individualized and based ...
Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.
Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.
FLT3 mutations are the most frequently identified ... for the treatment of patients with AML and CLL. We believe lonitoclax could be a first in class oral binder with superior potency and ...
Wael Gamal et al, Mitigating T-Cell Mitochondrial Dysfunction in CLL to Augment CAR T-Cell Therapy: Evaluation in an Immunocompetent Model, Blood Advances (2025). DOI: 10.1182/bloodadvances.2024014822 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results